SecBot SecBot
8-K ·Filed Nov 3, 2026

SYRE

Spyre Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed13d 9h ago SEC0001636282-26-000132
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The mixed clinical results (IBD monotherapies positive, rheumatic disease programs discontinued) combined with the recent $350M offering create a binary event profile. Key catalysts are the SKYLINE Part B combination data in Q3 2027 and SKYLIGHT HS data in late 2027/early 2028. The activist stake (Fairmount at 9.19%) adds pressure for pipeline execution.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

SYRE drug pipeline →

SPY002

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2
Time to market
SPY002 is in Phase 2 development. If SKYLINE Part B (combination) data in Q3 2027 is positive, a Phase 3 program would follow. Assuming successful development, potential approval would be several years away, likely in the 2029-2031 timeframe.
Next catalyst
None dated

What to watchThe next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027. Positive data would validate Spyre's combination strategy and could drive significant upside; negative data would undermine the entire platform thesis. The company also has SPY072 SKYWAY data and SKYLIGHT HS data as additional catalysts in late 2027/early 2028.

Price Chart

Loading chart...

Executive Summary

Spyre Therapeutics reported Q3 2026 results with a net loss of $96.1M, wider than the $11.2M loss in Q3 2025, driven by higher R&D spending. The company announced positive Phase 2 data for all three IBD monotherapies (SPY001, SPY002, SPY003) but SPY072 failed primary endpoints in PsA and axSpA and will not advance in rheumatic disease. Pro forma cash stands at $1.47B after a $350M October offering, funding operations into 2H 2029.

Key Financial Metrics

EPS
−$0.94

Key Facts

  • Net loss of $96.1M for Q3 2026 vs $11.2M in Q3 2025
  • Pro forma cash of $1.47B as of September 30, 2026, including $378M net from October offering and $18M ATM sales
  • SPY003 completed proof-of-concept for all three IBD monotherapies; Part B combination data expected Q3 2027
  • SPY072 failed primary endpoints in PsA and axSpA sub-studies; will not advance in rheumatic disease
  • New SKYLIGHT Phase 2 trial in HS initiated; topline data expected late 2027 or early 2028
  • R&D expenses $89.2M in Q3 2026 vs $45.2M in Q3 2025
  • Net cash used in operating activities was $77.5M for Q3 2026
  • Common shares outstanding increased to 89.95M from 78.19M at year-end 2025

Financial Impact

Net loss widened by $84.9M year-over-year; cash burn $77.5M in operating activities; $378M net proceeds from October offering

net losscash positionR&D expensesshare count

Risk Factors

  • SPY072 failure in PsA/axSpA raises questions about TL1A mechanism breadth beyond IBD
  • Cash burn rate accelerating ($77.5M operating cash flow in Q3 alone) despite $1.47B pro forma cash
  • Dilution from October offering (4.1M shares at $85) and ongoing ATM sales
  • All pipeline candidates are still in Phase 2; no approved products or revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001636282-26-000132
Document: syre-20261103.htm0001636282-26-000132
Document: 0001636282-26-000132-index-headers.html0001636282-26-000132
Document: 0001636282-26-000132-index.html0001636282-26-000132
Document: 0001636282-26-000132.txt0001636282-26-000132
8-K Data (Synthetic)0001636282-26-000132

Track record

36 reports on SYRE

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 Viewing No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens in 7h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026